Huimin Meng

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

Fengtao You, Licui Jiang, Bozhen Zhang et al. · Science China Life Sciences · 2016 · 153 citations · Full text

Medicine, Immunology, Oncology +17

A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.

Fengtao You, Yinyan Wang, Licui Jiang et al. · PubMed · 2019 · 130 citations · Full text

Life Sciences, Immunology, Oncology +12

Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Mingzhi Zhang, Dan Chen, Xiaorui Fu et al. · Clinical Cancer Research · 2022 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation

Shuai Li, Huimin Meng, Feng Zhou et al. · Pathology - Research and Practice · 2013 · 65 citations

Medicine, Molecular Biology, Oncology +16

Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells

Jinle Tang, Jialu Li, Xuejun Zhu et al. · Oncotarget · 2016 · 53 citations · Full text

Medicine, Hematology, Oncology +11